Cost-effectiveness analysis of interferon as adjuvant therapy in high-risk melanoma patients in Spain

By Gonzalez-Larriba J.L.   Serrano S.   Alvarez-Mon M.   Camacho F.   Casado M.A.   Daz-Perez J.L.   Daz-Rubio E.   Fosbrook L.   Guillem V.   Lopez-Lopez J.J.   Moreno-Nogueira J.A.   Toribio J.  

European Journal of Cancer, Vol. 36, Iss. 18, 2000-12 ,pp. : 2344-2352

Elsevier

Access to resources Recommend Favorite

Trastuzumab in adjuvant breast cancer therapy. A model based cost-effectiveness analysis

By Norum J.   Olsen J. A.   Wist E. A.   Lønning P. E.  

Acta Oncologica, Vol. 46, Iss. 2, 2007-01 ,pp. : 153-164

Informa Healthcare

Access to resources Recommend Favorite

Identification of a High-Risk Subgroup of Patients with Resected pT3 Oral Cavity Cancer in Need of Postoperative Adjuvant Therapy

By Liao Chun-Ta  

Annals of Surgical Oncology, Vol. 18, Iss. 9, 2011-09 ,pp. : 2569-2578

Springer Publishing Company

Access to resources Recommend Favorite

Intermediate dose interferon alpha in adjuvant treatment for high-risk melanoma: A single institution's experience

By Tas Faruk   Kurul Sidika   Camlica Hakan   Topuz Erkan  

Medical Oncology, Vol. 23, Iss. 4, 2006-12 ,pp. : 471-477

Humana Press, Inc

Access to resources Recommend Favorite

Adjuvant therapy of cutaneous melanoma – current status

By Hansson Johan  

Acta Oncologica, Vol. 45, Iss. 4, 2006-06 ,pp. : 369-372

Informa Healthcare

Access to resources Recommend Favorite